136 related articles for article (PubMed ID: 37670245)
1. The CA125 level postoperative change rule and its prognostic significance in patients with resectable pancreatic cancer.
Luo X; Lin X; Lin R; Yang Y; Wang C; Fang H; Huang H; Lu F
BMC Cancer; 2023 Sep; 23(1):832. PubMed ID: 37670245
[TBL] [Abstract][Full Text] [Related]
2. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
[TBL] [Abstract][Full Text] [Related]
3. Preoperative evaluation of pancreatic ductal adenocarcinoma with synchronous liver metastasis: Diagnosis and assessment of unresectability.
Shi HJ; Jin C; Fu DL
World J Gastroenterol; 2016 Dec; 22(45):10024-10037. PubMed ID: 28018110
[TBL] [Abstract][Full Text] [Related]
4. Preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after curative intent surgical resection.
Kim NH; Kim HJ
Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):450-455. PubMed ID: 30237091
[TBL] [Abstract][Full Text] [Related]
5. Clinical value of CEA and CA125 regarding relapse and metastasis in resectable non-small cell lung cancer.
Gaspar MJ; Diez M; Rodriguez A; Ratia T; Martin Duce A; Galvan M; Granell J; Coca C
Anticancer Res; 2003; 23(4):3427-32. PubMed ID: 12926084
[TBL] [Abstract][Full Text] [Related]
6. Development of a Biomarker-Based Scoring System Predicting Early Recurrence of Resectable Pancreatic Duct Adenocarcinoma.
Ishido K; Kimura N; Wakiya T; Nagase H; Hara Y; Kanda T; Fujita H; Hakamada K
Ann Surg Oncol; 2022 Feb; 29(2):1281-1293. PubMed ID: 34608555
[TBL] [Abstract][Full Text] [Related]
7. Postoperative serum CA19-9, CEA and CA125 predicts the response to adjuvant chemoradiotherapy following radical resection in pancreatic adenocarcinoma.
Xu HX; Li S; Wu CT; Qi ZH; Wang WQ; Jin W; Gao HL; Zhang SR; Xu JZ; Liu C; Long J; Xu J; Ni QX; Yu XJ; Liu L
Pancreatology; 2018 Sep; 18(6):671-677. PubMed ID: 30153903
[TBL] [Abstract][Full Text] [Related]
8. Preoperative serum CA125 levels predict the prognosis in hyperbilirubinemia patients with resectable pancreatic ductal adenocarcinoma.
Chen T; Zhang MG; Xu HX; Wang WQ; Liu L; Yu XJ
Medicine (Baltimore); 2015 May; 94(19):e751. PubMed ID: 25984661
[TBL] [Abstract][Full Text] [Related]
9. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
[TBL] [Abstract][Full Text] [Related]
10. Serum CEA, CA125, and SCC antigens and tumor recurrence in resectable non-small cell lung cancer.
Diez M; Gomez A; Hernando F; Ortega MD; Maestro ML; Torres A; Mugüerza JM; Gutierrez A; Granell J; Balibrea JL
Int J Biol Markers; 1995; 10(1):5-10. PubMed ID: 7629428
[TBL] [Abstract][Full Text] [Related]
11. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.
Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL
Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876
[TBL] [Abstract][Full Text] [Related]
12. Does serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian cancer? Results of a 12-year study.
Guo N; Peng Z
J Ovarian Res; 2017 Mar; 10(1):14. PubMed ID: 28284216
[TBL] [Abstract][Full Text] [Related]
13. Who could complete and benefit from the adjuvant chemotherapy regarding pancreatic ductal adenocarcinoma? A multivariate-adjusted analysis at the pre-adjuvant chemotherapy timing.
Fu N; Qin K; Li J; Jin J; Jiang Y; Deng X; Shen B
Cancer Med; 2022 Sep; 11(18):3397-3406. PubMed ID: 35434972
[TBL] [Abstract][Full Text] [Related]
14. [Prognostic value of carcinoembryonic antigen, alpha fetoprotein, carbohydrate antigen 125 and carbohydrate antigen 19-9 in gastroenteropancreatic neuroendocrine neoplasms].
Chen L; Zhang Y; Chen M; Chen J
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1002-1008. PubMed ID: 28900990
[TBL] [Abstract][Full Text] [Related]
15. Normalization of CA19-9 following resection for pancreatic ductal adenocarcinoma is not tantamount to being cured?
Chen T; Zhang MG; Yu XJ; Liu L
Asian Pac J Cancer Prev; 2015; 16(2):661-6. PubMed ID: 25684504
[TBL] [Abstract][Full Text] [Related]
16. The metastasis status and tumor burden-associated CA125 level combined with the CD4/CD8 ratio predicts the prognosis of patients with advanced pancreatic cancer: A new scoring system.
Yang C; Cheng H; Luo G; Lu Y; Guo M; Jin K; Wang Z; Yu X; Liu C
Eur J Surg Oncol; 2017 Nov; 43(11):2112-2118. PubMed ID: 28802662
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancer.
Hata S; Sakamoto Y; Yamamoto Y; Nara S; Esaki M; Shimada K; Kosuge T
Ann Surg Oncol; 2012 Feb; 19(2):636-41. PubMed ID: 21863360
[TBL] [Abstract][Full Text] [Related]
18. The significance of the change pattern of serum CA125 level for judging prognosis and diagnosing recurrences of epithelial ovarian cancer.
Yang ZJ; Zhao BB; Li L
J Ovarian Res; 2016 Sep; 9(1):57. PubMed ID: 27629537
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of C-reactive protein-to-prealbumin ratio in predicting early recurrence in resectable pancreatic cancer.
Kwon CH; Seo HI; Kim DU; Han SY; Kim S; Lee NK; Hong SB; Ahn JH; Park YM; Noh BG
Korean J Clin Oncol; 2023 Jun; 19(1):11-17. PubMed ID: 37449394
[TBL] [Abstract][Full Text] [Related]
20. Serum CA125 is a novel predictive marker for pancreatic cancer metastasis and correlates with the metastasis-associated burden.
Liu L; Xu HX; Wang WQ; Wu CT; Xiang JF; Liu C; Long J; Xu J; Fu de L; Ni QX; Houchen CW; Postier RG; Li M; Yu XJ
Oncotarget; 2016 Feb; 7(5):5943-56. PubMed ID: 26745601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
